黄 玲 药物化学博士 教授 博士生导师

2011年6月毕业于中山大学获药物化学博士学位，同年留校任教，2015年1月晋升为副教授，2015年荣获广东省“特支计划”科技创新青年拔尖人才和广州市珠江科技新星专项人才称号，2016年赴美国Scripps研究所神经生物学系访学一年，2018年评为博士生导师。2021年通过高层次人才引进到海南大学工作。

电子邮箱：Linghuang@hainanu.edu.cn

1.教育经历

2006.09~2011.06：中山大学药学院，博士（硕博连读）；

2000.09~2004.06：中南大学药学院，本科；

2.科研情况

课题组面向国家重大需求，针对“高效设计和发现神经退行性疾病创新药物”重大科学难题，结合药物化学、化学生物学、神经药理学等理论及实验技术，长期致力于神经退行性疾病创新药物设计与发现研究工作，取得了重要成果，在J. Med. Chem.、Eur. J. Med. Chem.等国际期刊发表SCI论文61篇，其中第一作者或通讯作者论文39篇（其中中科院大类一区top期刊论文11篇/JCR分区Q1论文19篇，JCR分区Q2论文18篇），他引2000余次，3篇论文他引超过100次，单篇最高他引151次，h-index 30。申请中国发明专利15项，已获授权专利4项。主持国家自然科学基金面上项目，青年科学基金、广东省自然科学基金等10余项课题。

3.研究领域

神经退行性疾病创新药物设计与发现

4.主持的科研项目：

1）海南大学C类高层次人才引进经费，300万，2021-2025，主持

2）国家自然科学基金面上项目:新型多靶点抗阿尔茨海默病喹啉衍生物：设计合成、生物活性与分子机制研究，64.0万元，2018 - 2021，主持

3）广东省“特支计划”科技创新青年拔尖人才项目，30.0万元，2016 -2019

4）广州市珠江科技新星专项，30.0万元，2016 -2019，主持

5）广东省自然科学基金面上项目：多靶点抗阿尔茨海默病药物分子设计合成、活性研究及作用机制探索；10.0万元，2015-2018，主持

6）中山大学高校基本科研业务费青年教师培育项目：靶向Aβ神经毒性机制网络的苯并异硒唑酮喹啉衍生物的设计合成及其抗阿尔茨海默病作用研究；15.0万元，2015 -2018，主持

7）国家自然科学基金青年基金：基于多靶点策略的茚酮衍生物的设计合成与抗阿尔茨海默病活性及作用机制研究，25.0万元，2014 - 2016，主持

5.第一作者或通讯作者论文

1）JinhuiHu, TingtingPan, BaijiaoAn, ZhengcunxiaoLi , XingshuLi*,Huang, Ling*. Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease.Eur.J.Med.Chem., 2019, 512− 526.

2）JinhuiHu, , Ya-DanHuang, TingtingPan, TianhuaZhang , TaoSu, XingshuLi , Hai-BinLuo, *LingHuang,*. Design, Synthesis, and Biological Evaluation of Dual-Target Inhibitors of Acetylcholinesterase (AChE) and Phosphodiesterase 9A (PDE9A) for the Treatment of Alzheimer's Disease.ACS Chem.Neurosci, 2019, 10, 537−551.

3）Tingting Pan,Shishun Xie, Yan Zhou, Huijin Hu, Haibin Luo, Xingshu Li,Ling Huang *. Dual functional cholinesterase and PDE4D inhibitors for the treatment of Alzheimer's disease: Design, synthesis and evaluation of tacrine-pyrazolo [3,4-b] pyridine hybrids.Bioorg. Med. Chem. Lett,2019, 29 (16), 2150-2152

4）Zhiren Wang, Jinhui Hu, Xiaoping Yang, Xing Feng, Xingshu Li,*Ling Huang,*and Albert S. C. Chan. Design, Synthesis, and Evaluation of Orally Bioavailable Quinoline–Indole Derivatives as Innovative Multitarget-Directed Ligands: Promotion of Cell Proliferation in the Adult Murine Hippocampus for the Treatment of Alzheimer’s Disease.J. Med. Chem.2018, 61, 1871-1894.

5）Baijiao An, Bo Wang, Jinhui Hu, Shaoyu Xu,Ling Huang,*Xingshu Li,* and Albert S. C. Chan. Synthesis and Biological Evaluation of Selenium-Containing 4-Anilinoquinazoline Derivatives as Novel Antimitotic Agents.J. Med. Chem. 2018,61, 2571-2588.

6）JinhuiHu, BaijiaoAn, TingtingPan, ZhengcunxiaoLi, ,Huang, Ling*, XingshuLi. Design, synthesis, and biological evaluation of histone deacetylase inhibitors possessing glutathione peroxidase-like and antioxidant activities against Alzheimer's disease,Bioorg Med Chem, 2018, 26, 5718-5729.

7）Chuan-Jun Lu, Jinhui Hu, Zechen Wang, Shishun Xie, Tingting Pan,LingHuang*,Xingshu Li. Discovery of boron-containing compounds as Aβ aggregationinhibitors and antioxidants for the treatment of Alzheimer's disease,MedChemComm, 2018,9, 1862-1870.

8）Shun Zhang, Baijiao An, Jiayan Li, Jinhui Hu,Ling Huang,*Xingshu Li * and Albert S. C. Chan. Synthesis and evaluation of selenium-containing indole chalcone and diarylketone derivatives as tubulin polymerization inhibition agents.Org. Biomol. Chem.,2017, 15, 7404 – 7410.

9）Jun Yan, Jie Chen, Shun Zhang, Jinhui Hu,Ling Huang,*and Xingshu Li*. Synthesis, Evaluation, and Mechanism Study of Novel IndoleChalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo.J. Med. Chem.2016, 59, 5264−5283.

10）Tao Su, Tianhua Zhang, Shishun Xie, JunYan, Yinuo Wu, Xingshu Li,Ling Huang,*and Hai-Bin Luo *. Discovery of novel PDE9 inhibitors capable of inhibiting Aβ aggregation as potential candidates for the treatment of Alzheimer’s disease.Sci. Rep. 2016, (6), 1-14. Zhiren Wang, Wenrui Li, Yali Wang, Xiruo Li,Ling Huang,*Xingshu Li*. Design, synthesis and evaluation of clioquinol-ebselen hybrids as multi-target-directed ligands against Alzheimer's disease.RSC Adv. 2016, 7139-7158.

11）Yali Wang, Yang Sun, Yueyan Guo, Zechen Wang,Ling Huang*,Xingshu Li. Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer’s disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives.J. Enzyme. Inhib. Med. Chem.2016, 31(3), 389-397.

12）Zhiren Wang, Yali Wang, Bo Wang, Wenrui Li,Ling Huang,*and Xingshu Li*. Design, Synthesis and Evaluation of Orally Available Clioquinol-Moracin M Hybrids as Multi-Target-Directed Ligands for Cognitive Improvement in a Rat Model of Neurodegeneration in Alzheimer’s Disease.J. Med. Chem.2015, 8616–8637.

13）Zhiren Wang, Yali Wang, Wenrui Li, Zhihong Liu, Zonghua Luo, Yang Sun, Ruibo Wu,Ling Huang,*and Xingshu Li*. Computer-assisted designed “selenoxy–chinolin”: a new catalytic mechanism of the GPx-like cycle and inhibition of metal-free and metal-associated Aβ aggregation. Dalton Trans., 2015, 44, 20913-25.

14）Jun Yan, Yueyan Guo, Yali Wang, Fei Mao,Ling Huang*,,Xingshu Li *. Design, synthesis, and biological evaluation of benzoselenazole-stilbene hybrids as multi-target-directed anti-cancer agents.Eur. J. Med. Chem. 2015, 95, 220-229.

15）Jun Yan, Yanqing Pang, Jie Chen, Jianfei Sheng, Jinhui Hu,Ling Huang,*and Xingshu Li*. Synthesis, biological evaluation and mechanism study of a class of cyclic combretastatin A-4 analogues as novel antitumour agents.RSC Adv. 2015, 98527-98537.

16）Jie Chen, Jun Yan, Jinhui Hu, Yanqing Pang,Ling Huang*,Xingshu Li*. Synthesis, Biological Evaluation and Mechanism Study of Chalcone Analogues as Novel Anti-cancer Agents.RSC Adv. 2015, 5, 68128-68135.

17）Shishun Xie, Jie Chen, Xiruo Li, Tao Su, Yali Wang, Zhiren Wang,Ling Huang*,Xingshu Li*. Synthesis and evaluation of selegiline derivatives as monoamine oxidase inhibitor, antioxidant and metal chelator against Alzheimer's disease.Bioorg. Med. Chem.,2015, 23, 3722–3729.

18）Jinhui Hu, Jun Yan, Jie Chen, Yangqing Pan,Ling Huang*,,Xingshu Li *.Synthesis, biological evaluation and mechanism study of a class of benzylideneindanone derivatives as novel anticancer agents.MedChemComm.,2015,6, 318-1327.

19）Tao Su, Shishun Xie, Bifu Li, Jun Yan,Ling Huang,*Xingshu Li*. Copper-catalyzed three-component one-pot synthesis of substituted 2-aryl-1,3-benzoselenazoles.Synlett.2015, 26, 215-220.

20）Fei Mao, Jianheng Li, Hui Wei,Ling Huang,*Xingshu Li*. Tacrine–propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of Alzheimer’s disease.J. Enzyme. Inhib. Med. Chem.2015, 995-1001. Zhiren Wang , Yali Wang, Wenrui Li, Fei Mao, Yang Sun,Ling Huang*,,Xingshu Li *. Design, synthesis, and evaluation of multitarget-directed selenium-containing clioquinol derivatives for the treatment of Alzheimer's disease.ACS Chem. Neurosci. 2014, 5, 952− 962.

21）Jianfei Sheng, Fei Mao, Jun Yan , Ling Huang *, Xingshu Li*.The convenient aqueous synthesis and biological evaluation of ortho-(3,4,5-trimethoxybenzoyl)-acetanilides as novel anti-cancer agents.RSC Adv.,2014, 4, 41510 - 41520.Ling Huang,Hui Miao, Yang Sun, Fanchao Meng, Xingshu Li*. Discovery of indanone derivatives as multi-target-directed ligands against Alzheime r's disease.Eur. J. Med. Chem. 2014, 87, 429 - 439.Ling Huang,Wenjun Shan, Qi Zhou, Jiaxing Xie, Kefang Lai, Xingshu Li*. Design, synthesis and evaluation of dual pharmacology β2-adrenoceptor agonists and PDE4 inhibitors.Bioorg. Med. Chem. Lett.2014, 24, 249–253.Fei Mao, Jun Yan, Jianheng Li, Xian Jia, Hui Miao, Yang Sun, Ling Huang* , Xingshu Li*. New multi-target-directed small molecules against Alzheimer ’ s disease: a combination of resveratrol and clioquinol.Org. Biomol. Chem., 2014, 12, 5936 –5944.

22）Chuanjun Lu, Yueyan Guo, Jun Yan, Zonghua Luo, Hai-Bin Luo, Ming Yan,Ling Huang*,Xingshu Li*. Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer's Disease.J. Med. Chem.2013, 56(14), 5843−5859

23）Zonghua Luo , Jianfei Sheng, Yang Sun, Chuanjun Lu, Jun Yan, Anqiu Liu, Hai-Bin Luo,Ling Huang*,Xingshu Li*. Synthesis and evaluation of multi-target-directed ligands against Alzheimer’s disease based on the fusion of donepezil and ebselen.J. Med. Chem.2013, 56, 9089− 9099.

24）Ling Huang,Tao Su, Xingshu.Li*. Natural Products as Sources of New Lead Compounds for the Treatment of Alzheimer's Disease.Curr. Top. Med. Chem.2013, 13(15), 1864-1878.

25）Chuanjun Lu , Qi Zhou, Jun Yan, Zhiyun Du,Ling Huang*,Xingshu Li*. A novel series of tacrine-selegiline hybrids with cholinesterase and monoamine oxidase inhibition activities for the treatment of Alzheimer’s disease.Eur. J. Med. Chem. 2013, 62, 745-753.

26）Tao Su, Shishun Xie, Hui Wei, Jun Yan,Ling Huang*,Xingshu Li*.Synthesis and biological evaluation of berberine–thiophenyl hybrids as multi-functional agents: Inhibition of acetylcholinesterase, butyrylcholinesterase, and Aβ aggregation and antioxidant activity.Bioorg. Med. Chem.2013, 21(18), 5830–5840.

27）Ling Huang,Chuanjun Lu, Yang Sun, Fei Mao, Zonghua Luo, Tao Su, Huailei Jiang, Wenjun Shan, Xingshu Li*. Multitarget-Directed Benzylideneindanone Derivatives: Anti-β-Amyloid (Aβ) Aggregation, Antioxidant, Metal Chelation, and Monoamine Oxidase B (MAO-B) Inhibition Properties against Alzheimer’s Disease.J. Med. Chem.2012, 55(19), 8483− 8492.

28）Yang Sun, Jianwen Chen, Xuemin Chen,Ling Huang*,Xingshu Li*. Inhibition of cholinesterase and monoamine oxidase-B activity by Tacrine–Homoisoflavonoid hybrids.Bioorg. Med. Chem.2013, 21(23), 7406–7417.

29）Ling Huang,Su Tao, Wenjun Shan, Zonghua Luo, Yang Sun and Xingshu Li*. Inhibition of Cholinesterase activity and Amyloid aggregation by Berberine- phenyl-benzoheterocyclic and Tacrine-phenyl-benzoheterocyclic hybrids.Bioorg. Med. Chem.2012, 20(9), 3038-3048.

30）Meng, Fan-Chao, Mao, Fei; Shan, Wen-Jun; Qin, Fangfei;Huang, Ling*,Li Xing-Shu*. Design, synthesis, and evaluation of indanone derivatives as acetylcholinesterase inhibitors and metal-chelating agents,Bioorg. Med. Chem. Lett.,2012, 22(13), 4462–4466.

课题组长期招聘药物化学，药理学，有机化学，生物学等相关专业的研究员、博士后。

欢迎具有药学、化学、生物学背景的同学报考本课题组研究生。